Skip to main content

What the FDA labels say about taking them together

Abemaciclib and camizestrant

Camizestrant's FDA label of September 4, 2026 names abemaciclib in its drug interactions section; the abemaciclib label PlainMeds reads does not name camizestrant. The camizestrant label: “If concomitant use with a moderate CYP3A inducer cannot be avoided, dose adjustment is needed when ETCAMAH is given in combination with abemaciclib or palbociclib.”

Check it at the source: the abemaciclib FDA label on DailyMed (effective July 13, 2026, Eli Lilly and Company); the camizestrant FDA label on DailyMed (effective September 4, 2026, AstraZeneca Pharmaceuticals LP).

What does the abemaciclib label say about camizestrant?

Abemaciclib's label (effective July 13, 2026) does not name camizestrant in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Verzenio), Eli Lilly and Company, effective July 13, 2026 (SPL set be4bc0de-0fdc-4d46-8d25-be43c79e6a06), via openFDA; the full label on DailyMed

What does the camizestrant label say about abemaciclib?

Camizestrant label, drug interactions

If concomitant use with a moderate CYP3A inducer cannot be avoided, dose adjustment is needed when ETCAMAH is given in combination with abemaciclib or palbociclib.

Source: FDA drug label (ETCAMAH), AstraZeneca Pharmaceuticals LP, effective September 4, 2026 (SPL set c54223d3-f3c7-4186-afa0-429d84805826), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Abemaciclib generic labelers
0Camizestrant generic labelers
AbemaciclibCamizestrant
Labeled forBreast cancern/a
Boxed warningNoYes
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?